Anti-BRAF V600E (Hu), ms clone HA01

Product Overview

• Article Name: Anti-BRAF V600E (Hu), ms clone HA01
• Biozol Catalog Number: DNA-DIA-HA01
• Supplier Catalog Number: DNA-DIA-HA01
• Alternative Catalog Number: DIA-HA01,DNA-DIA-HA01
• Manufacturer: dianova
• Host: Mouse
• Category: Antikörper
• Application: IHC
• Species Reactivity: Human
• Immunogen: Synthetic peptide, amino acid sequence CKPIIIGHHAYGD
• Alternative Names: BRAF, BRAF V600E

Product Description

Regulatory Status: RUO

Additional Information

Clone HA01 reacts specifically with the BRAF V600E point mutation in tissue sections from routine formalin-fixed paraffin embedded human tumors (IHC FFPE). This antibody has been validated for the identification of BRAF V600E positive cells in diverse human tumor tissues with an additional focus on neuropathological tumor tissues selected according to WHO guidelines.

 

Background

BRAF V600E is a well-established oncogenic driver mutation with broad clinical implications. Since first studies of BRAF mutations in cancers 2002 (1), BRAF V600E has evolved into a critical diagnostic, prognostic, and predictive tumor marker. BRAF has been shown to be mutated in various types of cancers including malignant melanoma (~50%), papillary thyroid cancer (~45%), colorectal cancers (~10%) and has also been identified in ovarian, breast, and lung cancers (1,2,3). Several primary CNS neoplasms harbor a BRAF V600E mutation, e.g. several pediatric low-grade gliomas (4,5): ~60% of pleomorphic xanthoastrocytomas (PXA), 20–60% of gangliogliomas (GG), and roughly 10% of pilocytic astrocytomas.

Physiologically, BRAF acts as a serine-threonine protein kinase and is a member of the RAF kinase family playing an important role in the RAS-RAF-MAPK signaling pathway, which regulates cell survival, proliferation and differentiation (6). 90% of oncogenic mutations in the BRAF gene are a single V600E substitution within the kinase domain and result in sustained kinase activity, constitutively activating the MAPK signaling pathway which leads to carcinogenesis (7,8).

 

Instructions for Use

Immunohistochemical (IHC) staining of standard formalin-fixed paraffin sections: Heat induced epitope retrieval (HIER) is required. Different detection techniques can be used: Indirect immunoenzyme labeling with a secondary antibody conjugate, biotin/(strept)avidin-based detection, soluble enzyme immune complex or polymer-based detection. To detect antibody, follow the instructions provided with the particular visualization system. The antibody is suited for IHC staining using automated platforms (Ventana: CC1 pretreatment / Optiview detection). Use the antibody at 1:100 -1:200 dilution.

 

References

1. Davies H et al. Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
2. Dhomen N et al.BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am 23:529-545, 2009
3. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262, 2005
4. Schindler G, Capper D et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol.121(3):397-405, 2011.
5. Andrews LJ et al. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro-Oncology, 24(4):528-540, 2022
6. Wang XJ, Kim A, Li S. Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia. Int J Clin Exp Pathol. 7(7):4323-4328, 2014
7. Shinozaki E et al. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal ab treatment in patients with pretreated metastatic colorectal cancer. Br JCancer 117(10):1450-1458, 2017
8. Tan YH, Liu Y, Eu KW, Ang PW, Li WQ, Salto-Tellez M, et al. Detection of BRAF V600E mutation by pyrosequencing. Pathology 40(3): 295-298, 2008

 

Product Specifications

• Artikelnummer: DIA-HA01
• Spezifität:

  BRAF V600E

• Spezies-Reaktivität:

  Human

• Immunogen:

  Synthetisches Peptid, Aminosäuresequenz CKPIIIGHHAYGD

• Wirtsspezies:

  Maus

• Isotyp:

  IgG2b

• Klon:

  HA01

• Klonalität (Mono-/Polyklonal):

  monoklonal

• Anwendung:

  Immunhistochemie (IHC), Immunhistochemie (Paraffingewebe)

• Verdünnung:

  Histo-/Zytochemie 1:100

• Format:

  0,05% NaN3, 2% BSA, gereinigter Antikörper (aus Kulturüberstand), in PBS (pH 7,4), Lyophilisat

• Produktlinie / Thema:

  Neurobiologie, Tumormarker/-biologie

• Zweckbestimmung:

  nur für Forschungszwecke

• Temperatur - Lagerung:

  2-8°C

• Temperatur - Transport:

  bei Raumtemperatur

• Suchcode:

  DIAHA01, IHC, FFPE, Paraffin

• Hersteller / Marke:

  dianova

• Uniprot_ID:

  P15056

• Gene_ID:

  673

• Alias:

  BRAF, BRAF V600E

Product Properties

• Clonality: Monoclonal
• Clone Designation: HA01
• Isotype: IgG2b
• UniProt: P15056
• Form: 0.05% NaN3, 2% BSA, in PBS (pH 7.4), lyophilisate, purified antibody (from culture supernatant)
• Storage: 2-8°C
• Target: BRAF V600E
• Antibody Type: Monoclonal Antibody

Application Notes

• Application Dilute: Histo-/Cytochemistry 1:100

Images

Immunohistochemistry Ganglioglioma with BRAVV600E clone HA01 in formalin-fixed paraffin-embedded tissue

Immunohistochemistry Papillary Craniopharyngioma with BRAVV600E clone HA01 in formalin-fixed paraffin-embedded tissue

Immunohistochemistry Pleomorphic_Xanthoastrocytoma with BRAVV600E clone HA01 in formalin-fixed paraffin-embedded tissue

Immunohistochemistry Pilocytic_Astrocytoma with BRAVV600E clone HA01 in formalin-fixed paraffin-embedded tissue

Immunohistochemistry Neuroepithelial tumor (PLNTY) with BRAVV600E clone HA01 in formalin-fixed paraffin-embedded tissue

Immunohistochemistry Neuroepithelial tumor (PLNTY) with BRAVV600E clone HA01 in formalin-fixed paraffin-embedded tissue